TNFSF11 and prostate carcinoma: These outcomes may be a RANKL pathway-specific effect: Results from the Zometa European Study (ZEUS), which compared standard therapy with and without zoledronic acid treatment in patients with high risk prostate cancer, suggest that zoledronic acid treatment does not improve either overall survival or the incidence of bone metastasis [49].